Primary immune thrombocytopenia is an autoimmune disorder associated with a decreased prephiral blood platelet count. The phenotype is variable with a few instances struggling no bleeding while others have extreme bleeding which may be deadly. Variability in clinical behaviour and remedy responses reflects its complicated pathophysiology. Traditionally the management has relied heavily on immune suppression. latest studies have shown that the older empirical immune suppressants fail to adjust the natural history of the complaint and are associated with a bad exceptional life for patients. More recent remedies, the thrombopoietin receptor agonists, have converted ITP care. they've excessive efficacy, are nicely tolerated and ameliorate cases ’ high-quality of lifestyles. An extra expertise of the underpinning pathophysiology of this criticism has helped development more recent targeted curatives. These consist of inhibitors of the neonatal Fc receptor inhibitors, Bruton tyrosine kinase and supplement pathway. Then we bandy the mechanisms underlying ITP and the new method to ITP care
